NCT01354093View on ClinicalTrials.gov

The Role of Macular Pigment Carotenoids in the Pathogenesis and Treatment of Macular Telangiectasia Type 2 (MacTel)

CompletedOBSERVATIONAL
Enrollment

8

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

January 31, 2017

Study Completion Date

January 31, 2017

Conditions
Idiopathic Juxtafoveal Telangiectasia
Interventions
DRUG

zeaxanthin

10 mg of EyePromise 10 (zeaxanthin) supplement, taken twice a day

DRUG

zeaxanthin

10 mg of EyePromise 10 (zeaxanthin) supplement, taken once a day

Trial Locations (1)

84132

Moran Eye Center, University of Utah, Salt Lake City

All Listed Sponsors
lead

Paul S. Bernstein

OTHER

NCT01354093 - The Role of Macular Pigment Carotenoids in the Pathogenesis and Treatment of Macular Telangiectasia Type 2 (MacTel) | Biotech Hunter | Biotech Hunter